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Abstract
Background: A vaccine to decrease transmission of human immunodeficiency virus type 1 (HIV-1) during breast-
feeding would complement efforts to eliminate infant HIV-1 infection by antiretroviral therapy. Relative to adults,
infants have distinct immune development, potentially high-risk of transmission when exposed to HIV-1 and rapid
progression to AIDS when infected. To date, there have been only three published HIV-1 vaccine trials in infants.
Trial Design: We conducted a randomized phase I clinical trial PedVacc 001 assessing the feasibility, safety and
immunogenicity of a single dose of candidate vaccine MVA.HIVA administered intramuscularly to 20-week-old infants
born to HIV-1-negative mothers in The Gambia.
Methods: Infants were followed to 9 months of age with assessment of safety, immunogenicity and interference with
Expanded Program on Immunization (EPI) vaccines. The trial is the first stage of developing more complex prime-
boost vaccination strategies against breast milk transmission of HIV-1.
Results: From March to October 2010, 48 infants (24 vaccine and 24 no-treatment) were enrolled with 100%
retention. The MVA.HIVA vaccine was safe with no difference in adverse events between vaccinees and untreated
infants. Two vaccine recipients (9%) and no controls had positive ex vivo interferon-γ ELISPOT assay responses.
Antibody levels elicited to the EPI vaccines, which included diphtheria, tetanus, whole-cell pertussis, hepatitis B virus,
Haemophilus influenzae type b and oral poliovirus, reached protective levels for the vast majority and were similar
between the two arms.
Conclusions: A single low-dose of MVA.HIVA administered to 20-week-old infants in The Gambia was found to be
safe and without interference with the induction of protective antibody levels by EPI vaccines, but did not alone
induce sufficient HIV-1-specific responses. These data support the use of MVA carrying other transgenes as a
boosting vector within more complex prime-boost vaccine strategies against transmission of HIV-1 and/or other
infections in this age group.
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Introduction
An unacceptably high number of children become infected
with the human immunodeficiency virus type 1 (HIV-1) every
year [1]. The majority of children who become infected with
HIV-1 acquire the virus from their infected mothers during
pregnancy, labour, delivery or breast-feeding. Although
approximately 42% of mother-to-child transmission (MTCT) is
due to prolonged breast-feeding [2-4], for many HIV-1-positive
mothers formula feeding is not an option for social, practical
and health reasons; breast-feeding reduces infant mortality due
to nutrition and protection against other common childhood
diseases [5]. Although antiretroviral therapy (ART) can
significantly reduce the risk of MTCT, ARTs reach
approximately 57% of HIV-1-infected mothers in low- and
middle-income countries [6], and residual MTCT can occur
despite ART [7]. Thus, development of safe, effective,
accessible vaccines to decrease the prevalence of HIV-1
among mothers and to protect infants against their mother’s
HIV-1 in the breast milk is a desired complement to the
successful prevention of mother-to-child transmission of HIV-1
by ART and ultimately the best solution.
Results of the first vaccine efficacy trials in adults suggested
that an eventual successful anti-HIV-1 vaccine may need to
induce both T cells and broadly neutralizing antibodies [8]. For
protection against breast-milk HIV-1, immune responses must
be elicited as early as possible after birth, and this will require
priming at or soon after delivery followed by boost
vaccination(s) within the first few months of life.
The natural history of HIV-1 infection and responsiveness to
vaccinations may differ in adults and infants young/children
[9,10], and parallel adult and paediatric clinical trials are
required [11]. To date, there have been three published studies
of active immunization in infants, which together evaluated 3
different Env-derived subunit proteins and 3 canarypox virus
(ALVAC)-vectored vaccines. Thus, Pediatric AIDS Clinical
Trials Group (PACTG) protocol 230 in the USA assessed
safety and immunogenicity of Chiron gp120SF-2 adjuvanted with
MF59 and VaxGen pg120MN adsorbed into alum [12-14].
PACTG 326 carried out mainly in the USA conducted phase 1
testing of ALVAC vCP205 (expressing clade B GagProtLAI and
gp120MN), and in phase 2 ALVAC vCP1452 (expressing clade
B GagProtLAI plus several human T cell epitopes from Nef and
Pol, and gp120MN attached to the gp41LAI transmembrane
region) followed by a boost with AIDSVAX B/B [15] mixed
gp120MN and gp120GNE8 in alum; the first doses of rALVAC
vaccines were delivered within 72 hours after birth [16,17].
Finally, the first African vaccine infant trial designated HIV
Prevention Trials Network (HPTN) protocol 027 administered
RV144 [18] ALVAC vCP1521 (expressing clade B GagProtLAI
and clade E gp12092TH023 linked to the transmembrane region of
gp41LAI) to infants born to HIV-1-infected mothers in Uganda
[19]. All vaccines in these three trials were safe and induced
immune responses broadly similar to those observed in adults
[20].
Modified vaccinia virus Ankara (MVA) is a highly attenuated
non-replicating (in humans) poxvirus with an excellent safety
and immunogenicity profile established in over 120,000 people
vaccinated as a part of the smallpox eradication campaign [21]
and its use as a vector for vaccines against a range of
pathogens [22]. In the past, we designed and constructed
immunogen HIVA (HIV clade A), which consists of consensus
HIV-1 clade A Gag p24/p17 coupled to a string of partially
overlapping CD8+ T-cell epitopes [23]. The HIVA vaccines were
tested comprehensively pre-clinically including in non-human
primates, whereby MVA.HIVA was less immunogenic in infants
than in their mothers [24,25]. Delivered by DNA and MVA,
HIVA was extensively tested in adults in the UK and Africa [26].
MVA.HIVA was shown to be a weak primer for the transgene
product-specific CD4+ and CD8+ T-cells, but delivered a strong
boost to well primed (e.g. by natural HIV-1 infection) responses
[27-31]. With highly reassuring safety data from over 370 adult
volunteers in the UK and Africa [27,30,32-35], we decided to
start building foundations for testing vaccines against breast
milk transmission of HIV-1 in two sub-Saharan African sites,
The Gambia and Kenya, by using the ethics and regulatory
review processes, establishing/expanding local infant vaccine
trial capacity, and performing small vaccine trials PedVacc 001
and PedVacc 002 in infants born to HIV-1-uninfected and
HIV-1-infected mothers. Here, we report on the PedVacc 001
trial, which administered a single low dose of MVA.HIVA to
healthy 20-week-old infants born to HIV-1-uninfected mothers
in The Gambia. This was the first time that a recombinant MVA
vaccine with an HIV-1 transgene was administered to less than
1-year-old children in Africa.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design
The Pediatric Vaccine (PedVacc) 001 study was a single-
centre, phase I, open, randomized, no treatment-controlled
study of candidate HIV-1 vaccine MVA.HIVA compared to no
treatment control group. Randomization was generated by the
Centre for Statistics in Medicine, University of Oxford using
simple random sampling.
Ethics and regulatory approvals
Approvals for the PedVacc 001 clinical study were granted
by The Republic of The Gambia National Pharmaceutical
Services Medicine Board, The Gambia Government/Medical
Research Council (MRC) Joint Ethics Committee (ref.
SC1106), Oxford Tropical Research Ethics Committee
(OXTREC ref. 11 08) and The Stockholm Regional Ethics
Committee (ref. 2009/1591-31/1). The study was conducted
according to the principles of the Declaration of Helsinki (2008)
and complied with the International Conference on
Harmonization Good Clinical Practice guidelines. The trial was
registered at the Clinical Trials.gov www.clinicaltrials.gov (ref.
NCT00982579) and the Pan African Clinical Trials Registry
www.pactr.org (ref. PACTR2008120000904116).
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Study population
The study was conducted at the MRC field site in Sukuta, a
low-income peri-urban setting in the western region of The
Gambia [36]. Mothers with infants born at Sukuta Health
Centre were provided with study information and those
interested in participating were invited to undergo voluntary HIV
counseling and testing, since only infants of HIV-1/2-negative
mothers were eligible. Infants underwent their routine
Expanded Program on Immunization (EPI) vaccinations at 8,
12 and 16 weeks of age, namely Pentavalent vaccine
(diphtheria, tetanus, whole cell pertussis (DTwP), hepatitis B
virus (HBV) and Haemophilus influenzae type b (Hib)), oral
poliovirus vaccine (OPV) and 7-valent pneumococcal conjugate
vaccine (PCV-7) (all supplied by UNICEF, www.unicef.org)
(Table 1). At 16 weeks of age, eligibility criteria were assessed
and prospective written informed consent was obtained from all
mothers of participating infants by signing and thumb-printing a
filled form. Consent of fathers/partners was also sought, but
was not a condition for participation. Eligible infants had to be
healthy, afebrile, have no history of allergy or acute or chronic
diseases, have a normal physical examination, and have
received all EPI vaccines according to schedule. At a 19-week
screening visit, 5 ml of blood was taken for baseline pre-
vaccination immunogenicity, haematology and biochemistry
analysis. At 20 weeks of age, the baseline blood tests were
confirmed to be within range, eligible infants were randomized
using sealed envelopes and assigned to vaccine (n=24) and
no-treatment control (n=24) groups by a study nurse.
The study vaccine and its administration
MVA.HIVA is a recombinant non-replicating poxvirus, which
carries the HIVA immunogen transgene (Figure 1) inserted by
homologous recombination into the thymidine kinase locus of
the parental MVA genome under the early/late P7.5 promoter
[37]. MVA.HIVA was manufactured under current Good
Manufacturing Practice conditions by Impfstoffwerk Dessau-
Tornau (IDT), Germany. It was provided in vials of 200 μl at
5x108 plaque-forming units (PFU)/ml in 10 mM Tris-HCl buffer
pH 7.7 and 0.9% NaCl, and stored at -70°C. The appropriate
number of vials were transported to the field site on dry ice on
the day of administration, each vial was thawed at room
temperature immediately prior to use and used within 1 hour of
thawing. Participants in the vaccine group received a single
intramuscular dose of 5x10⁷ PFU of MVA.HIVA considered to
be a low adult dose, while the control group did not receive any
treatment. The first vaccinated infant was observed for 24
hours to ensure there were no immediate safety concerns prior
to vaccinating the remaining eligible participants. At
subsequent visits at the age of 21, 28 and 36 weeks, a medical
history was taken and a physical examination was performed.
Blood sampling schedule and blood sample handling
Laboratory personnel were blinded to group allocation. Five
ml of blood (4 ml EDTA and 1 ml clotted) was collected at 19,
21 and 28 weeks of age (i.e. pre-randomization, and 1 and 8
weeks post-randomization), and a 5-ml EDTA sample at 36
weeks (16 weeks post-randomization). MVA.HIVA
immunogenicity was tested at all 4 time points; haematology
and biochemistry at 19, 21 and 28 weeks; EPI vaccine antibody
responses were determined at 19 and 21 weeks; and HIV
Table 1. EPI vaccination schedule in The Gambia.
Age Vaccine
Birth BCG, OPV, HBV
8 weeks OPV, Pentavalent, PCV-7
12 weeks OPV, Pentavalent, PCV-7
16 weeks OPV, Pentavalent, PCV-7
9 months Measles, Yellow fever, OPV
Pentavalent (DTwP, Hib, HBV), where DTwP - diphtheria, tetanus, whole cell pertussis; HBV - hepatitis B virus; Hib - Haemophilus influenzae type b; OPV - oral poliovirus
vaccine; and PCV-7 – 7-valent pneumococcal conjugate vaccine
doi: 10.1371/journal.pone.0078289.t001
Figure 1.  A schematic diagram of the HIV-1 clade A (HIVA) immunogen.  The HIVA protein consists of consensus amino acid
sequences of clade A p24 and p17 Gag and a string of partially overlapping CD8+ T-cell epitopes identified in chronically infected
individuals [23]. Pool P90 of 15-mer peptides overlapping by 11 amino acids across the Gag portion is shown below the protein.
Pool P9 consisted of known CD8+ T-cell epitope peptides derived from the polyepitope region.
doi: 10.1371/journal.pone.0078289.g001
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testing was carried out at 28 weeks. Serum was collected from
clotted blood. EDTA blood was used for full blood count (FBC)
and HIV serology (week 28). Peripheral blood mononuclear
cells (PBMC) were isolated from blood collected into EDTA by
density gradient centrifugation on Lymphoprep cushion
(Fresenius Kabi, Oslo, Norway).
Safety monitoring
Vaccinated infants were monitored for 1 hour post-
vaccination for immediate adverse events (AE), and by a home
visit on each of the following two days to record AEs. At
subsequent clinic visits, a medical history was taken, infants
were examined and any AEs were documented. FBC,
creatinine, alanine transaminase (ALT) and alkaline
phosphatase (ALP) were tested at baseline (19 weeks) and at
1 week and 8 weeks post-vaccination. Local and systemic AEs
and blood parameter abnormalities were graded from 0-3 as
follows: absent (0), mild (1), moderate (2), severe (3).
Relationship to MVA.HIVA vaccination was graded from 0-3 as
follows: not related (0), possibly related (1), probably related
(2), definitely related (3). Results were reviewed weekly by the
trial safety monitor and externally monitored throughout the
study. An external Data Monitoring and Ethics Committee
reviewed safety data at 6 monthly intervals.
Ex-vivo IFN-γ ELISPOT assay
Freshly isolated PBMC were suspended at 1x106 cells/ml in
R10 complete medium (RPMI1640 medium plus 10% FCS, L-
glutamine, HEPES, sodium pyruvate, penicillin and
streptomycin) and 200 μl (2x105 cells) applied to each test well
of 96-well plates (S5EJ044I10, Millipore). PBMC were
stimulated in triplicate for reactivity to peptide pool 90 (P90)
representing 88 peptides from the Gag p24/p17 and pool 9
(P9) containing 25 peptides covering the CD8+ T cell
polyepitope regions of HIVA (Figure 1), both pools containing
1.5 μg/ml of each peptide. Phytohaemagglutinin (PHA) (10
mg/ml) and R10 alone were tested in triplicate wells as positive
and background controls, respectively. ELISPOT plates were
incubated at 37°C in 5% CO2 for 16 hours, and developed
using the recommended protocol. Purple spots in each well, or
spot-forming units (SFU), were read by the ELISPOT reader
(Autoimmune Diagnostika software version 5.0, Strassburg,
Germany). An assay failed quality control (QC) if the mean
background was >20 SFU/well (>100 SFU/106 PBMC), or
mean PHA response was <30 SFU/well (<150 SFU/106
PBMC). Poisson modeling was used to identify outliers among
replicates, which were excluded, and Bonferroni correction was
used for multiple testing. A response was considered positive if
the mean stimulated response was at least twice the mean
background response, and the ‘net response’ (background
subtracted) was ≥ 50 SFU/106 PBMC.
EPI vaccine antibody responses
Microsphere-based multiplex assays were performed at the
National Institute for Public Health and the Environment,
Bilthoven, The Netherlands to quantify serum IgG antibodies
against diphtheria toxin (Dtx), tetanus toxin (Ttx) and Hib as
described previously [38]. Anti-HBV surface antigen (HBsAg)
antibody levels were measured using an anti-HBsAg enzyme
immunoassay kit (ETI-AB-AUK-3, Diasorin, Italy). Type 1
poliovirus IgG levels were determined by a neutralization assay
as described previously [39].
Anti-HIV-1 antibody testing
The Murex HIV-1 1.2.0 antibody assay kit (ABBOTT Murex,
Dartford, UK) was used to test plasma samples for HIV-1
antibodies at 28 weeks of age.
Statistical analysis
Data were analyzed using Stata version 12 (StataCorp,
College Station, Texas) and Graphpad Prism software Version
6.0a (GraphPad Software Inc., California, USA). The
immunology, vaccine antibody, haematology and biochemistry
parameters were not normally distributed and non-parametric
tests were used: two-tailed Mann-Whitney tests were used to
compare variables between the vaccine and control groups and
Wilcoxon matched-pairs tests for comparisons of responses for
the same infants at different time points. A significance level of
p<0.05 was considered statistically significant.
Results
Trial participants
From March to October 2010, 64 infants were assessed for
eligibility, of which 51 were screened at 19 weeks of age and
48 were randomized at 20 weeks to the vaccine (n = 24) or
control (n = 24) groups (Figure 2). This was a pilot study with
primarily descriptive outcomes. Groups were comparable by
sex, age, weight and mid-upper-arm circumference (MUAC) on
the day of vaccination at 20 weeks of age and also comparable
at baseline (19 weeks) for WBC, creatinine, ALT and ALP
(Table 2). However, baseline haemoglobin was higher in the
vaccine group (11.3 g/dl vs. 10.8 g/dl; p=0.038). All 48 infants
completed the study and all provided 4 blood samples.
MVA.HIVA was well tolerated
There were no local reactions in the hour after MVA.HIVA
vaccination, and only 1 infant developed mild redness (<50
mm), which persisted for 2 days, but resolved by day 7. No
children showed signs of localized pain (Table 3).
There were no serious AEs throughout the study. Five
infants had mild AEs that were possibly vaccine related,
consisting of low-grade fever (n = 2), vomiting (n = 2), and low-
grade fever plus excessive crying (n = 1) (Table 3). A further 10
AEs in the vaccine group were considered unrelated to
MVA.HIVA vaccination (9 mild, 1 moderate), including eye
discharge (n = 2), rash (n = 1), and weight loss at 28 or 36
weeks (n = 7). The control group similarly had 3 cases of fever,
2 of rash and 7 cases of weight loss. One case of skin rash
was of moderate severity in both the vaccine and control
groups. There was no significant difference in weight or MUAC
between the control and vaccine groups at any time point (not
shown); and the 4 vaccinees and 5 control subjects who had
weight loss at 28 weeks all returned to acceptable weight-for-
age by 36 weeks of age.
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There were no clinically significant biochemical or
haematological abnormalities in vaccine recipients (Table 4).
Haemoglobin levels were within range with the exception of 1
vaccinated and 1 control infant with mild low values, and 1
control infant with a high value. High WBC and platelet counts
were observed at 21 and 28 weeks in both vaccinated and
unvaccinated participants at baseline and after vaccination,
although none were thought to be of clinical significance. The
ALT levels remained in range for all but one vaccinated infant
at baseline, and the creatinine level was low in up to one third
of infants in both groups (lowest value 16 mM), which was not
considered clinically significant. Alkaline phosphatase
remained within range for all infants at all time points.
Single low dose of MVA.HIVA did not induce sufficient
anti-HIV-1 responses
Immunogenicity of a single intramuscular low dose of
MVA.HIVA was assessed using an ex-vivo IFN-γ ELISPOT
assay. Altogether, 167 fresh PBMC samples of the total of 192
possible samples (48 infants x 4 time points) were assayed. Of
these, 2 samples (1.2%) failed QC because of high background
levels and none failed due to a low PHA response. None of the
infants had HIV-1-specific T-cell responses before vaccination
at 19 weeks of age. At 21 weeks, i.e. 1 week after the
MVA.HIVA administration, 2 of 22 (9%) vaccine recipients had
detectable HIV-1-specific, IFN-γ-producing T cells at net
frequencies of 93 and 70 SFU/106 PBMC, while no controls
Figure 2.  Trial Profile.  Diagram indicating the numbers of infants screened and followed up throughout the study.
doi: 10.1371/journal.pone.0078289.g002
Table 2. Baseline characteristics of study participants.
 Control Group (n=24) Vaccine Group (n=24) p value
Sex 55% Male 67% Male  
 45% Female 33% Female  
Age (week) 20.0 (19.0, 20.0) 20.0 (19.8, 20.8) 0.280
Weight (kg) 7.2 (6.7, 7.7) 7.3 (6.9, 7.6) 0.680
MUAC (cm) 15.0 (14.4, 15.5) 15.0 (14.4, 15.4) 0.925
Hb (g/dl) 10.8 (10.2, 11.2) 11.3 (10.6, 11.9) 0.038
WBC (x109 cell/l) 9.3 (7.9, 12.1) 9.1 (8.5, 11.8) 0.821
Platelets (x109 cell/l) 493.0 (395.8, 637.5) 545.0 (414.8, 582.0) 0.915
Creatinine (mM) 24.5 (22.0, 31.2) 26.0 (23.0, 38.5) 0.860
ALT (U/l) 20.5 (16.8, 28.0) 21.0 (17.0, 25.5) 0.901
ALP (U/l) 293 (247, 344) 304 (249, 355) 0.749
Median values are shown with the interquartile range (IQR) in brackets. p values are shown for comparisons between the vaccine and control groups using a two-tailed
Mann-Whitney U test. MUAC - mid upper arm circumference; Hb - haemaglobin; WBC - white blood cell count; ALT - alkaline transaminase; ALP - alkaline phosphatase.
doi: 10.1371/journal.pone.0078289.t002
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had detectable responses (Figure 3). There were no
responders in either group at 28 weeks of age and at 36 weeks
of age, one vaccinated and one unvaccinated infant had
weakly-positive responses. Comparing the vaccine and no-
treatment groups as a whole, only peptide pool P9-specific
responses at week 21 were statistically higher in vaccine
recipients (p = 0.013).
MVA.HIVA administration did not affect protective
antibody levels induced by EPI vaccines
Antibody levels elicited by EPI vaccines were compared
between MVA.HIVA vaccine recipients and untreated controls
at 19 and 21 weeks, i.e. 1 week before and 1 week after the
MVA.HIVA vaccination, respectively. This analysis showed that
the two groups had comparable antibody responses to Ttx, Hib,
HBV and OPV. All infants reached protective antibody levels
except for 1 non-responder to HBV vaccine in the vaccine
group at both 19 and 21 weeks, and 3 infants (2 vaccine
recipients and 1 control) with Hib antibodies below protective
levels at 21 weeks. Paired comparisons of antibody levels at 19
and 21 weeks showed that the control group, but not the
vaccine group had significantly lower anti-HBsAg antibody
levels at 21 weeks (p = 0.001) (Table 5). Dtx antibodies
declined significantly in both control and vaccine groups (p =
0.043 and 0.0011), and Ttx antibodies decreased in the
vaccine recipients only (p = 0.0053). Only the declines in Dtx
and Ttx antibodies in the vaccine group were statistically
significant after Bonferroni correction (p ≤ 0.0125), although
Table 3. Local and systemic AEs in the first 7 days of follow up.
 Vaccine Group (n=24) Control Group (n=24)
 Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
 Mild Moderate Severe Mild Moderate Severe
Pain 0 0 0 NA NA NA
Redness 1 (4.2%) 0 0 NA NA NA
Induration 0 0 0 NA NA NA
Scaling 0 0 0 NA NA NA
Blistering 0 0 0 NA NA NA
Fever 3 (12.5%) 3 (12.5%) 0 0 3 (12.5%) 0
Excessive crying 1 (4.2%) 0 0 0 0 0
Poor appetite 0 0 0 0 0 0
Vomiting 2 (8.3%) 0 0 0 0 0
Diarrhoea 0 0 0 2 (8.3%) 0 0
Poor weight gain 7 (29.2%) 0 0 7 (29.2%) 0 0
Cough 4 (16.7%) 0 0 2 (8.3%) 0 0
Note some infants had more than 1 adverse event. The control group did not receive a vaccine hence no local reactogenicity data were recorded.
doi: 10.1371/journal.pone.0078289.t003
Table 4. Frequency of biochemical and haematological abnormalities.
  Week 19 Week 21 Week 28
  Vaccine Control Vaccine Control Vaccine Control
Hb (g/dl) High 0 0 0 1 (4.3%) 0 0
8-14 Low 0 0 1 (4.3%) 0 0 1 (4.3%)
WBC (cell/l) High 2 (9.1%) 0 5 (26.3%) 7 (41.2%) 4 (20.0%) 6 (33.3%)
3.5-14x109 Low 0 0 0 0 0 0
Platelets (cell/l) High 6 (37.5%) 9 (60%) 4 (21.1%) 5 (27.8%) 6 (33.3%) 6 (33.3%)
150-600x109 Low 2 (12.5%) 0 1 (5.3%) 1 (5.6%) 0 0
Creatinine (mM) High 0 0 0 0 0 0
20-70 Low 0 0 4 (20.0%) 2 (9.1%) 6 (33.3%) 5 (26.3%)
ALT (U/l) High 1 (4.4%) 0 0 0 0 0
10-80 Low 0 0 0 0 1 (4.4%) 0
ALP (U/l) High 0 0 0 0 0 0
140-1000 Low 0 0 0 0 0 0
The first column shows unit in brackets with acceptable ranges below. Numbers of infants with values above (high) and below (low) the normal range are indicated on the
table with the percentage in brackets. Hb – hemoglobin; WBC – white blood cell count; ALT – alanine transaminase; ALP – alkaline phosphatase.
doi: 10.1371/journal.pone.0078289.t004
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they remained well above protective levels for all infants (Table
5).
MVA.HIVA recipients remained HIV test negative
No vaccinated infant was found to be positive for HIV-1 or
HIV-2 antibodies at 28 weeks of age, 8 weeks after the
MVA.HIVA vaccine was administered. This concurs with
previous results in adult trials [31].
Discussion
The PedVacc 001 trial was conducted as a capacity building,
feasibility and recombinant MVA safety study. The trial was
approved by regulatory and all ethics bodies, and successfully
recruited and retained 100% of infant-mother pairs. The
MVA.HIVA vaccine was well tolerated and safe, but on its own,
did not sufficient HIV-1-specific responses. PedVacc 001 is the
first infant vaccine trial using recombinant MVA with an HIV-1-
derived insert and only the second infant candidate HIV-1
vaccine trial conducted in sub-Saharan Africa. As such, this
study contributed to the preparedness for conducting future
infant HIV-1 vaccine trials in this region.
In the PedVacc 001 trial, candidate HIV-1 vaccine MVA.HIVA
demonstrated an excellent reactogenicity profile causing only a
small number of mild AEs. There were no vaccine-related or
other SAEs, no clinically significant haematological or
biochemical disturbances and no significant adverse effects on
infant growth; these results concur with studies of MVA-
vectored vaccines for other diseases [40,41]. All out-of-range
values for haematological and biochemical parameters were
considered mild and clinically insignificant. The fact that WBC,
platelet and creatinine values were frequently out of range in
both vaccine recipients and controls suggests that locally
appropriate ranges are wider than those adopted in this study.
Figure 3.  MVA.HIVA-elicited weak T-cell responses in fresh IFN-γ ELISPOT assay.  The net fresh ex-vivo ELISPOT
frequencies of IFN-γ-producing cells (mean of stimulated wells minus mean of negative control wells) to HIVA peptide pools P9 and
P90 at all 4 bleed time points for the control (Con) and vaccinated (Vac) groups are shown. The p value for the only statistically
significant difference between the two groups after Bonferroni correction is given. The median ‘mock’ no-peptide background
response across all wells on plates that passed QC was 5 SFU/106 PBMC (IQ range 0-20), and median PHA response was 1,850
SFU/106 PBMC (IQ range 1,065- 2,960).
doi: 10.1371/journal.pone.0078289.g003
Table 5. Tested antibody titres at 19 and 21 weeks of age elicited by EPI vaccines.
  Control p value (Control Vaccine p value (Vaccine p value Con vs Vac
EPI Vaccine Protective Level 19 weeks 21 weeks 19 vs 21 weeks) 19 weeks 21 weeks 19 vs 21 weeks) 19 week 21 week
Poliovirus 1 ≥8 512 1024 0.313 512 512 0.629 0.765 0.616
(neut. titre)  (256, 1024) (224, 1024)  (128, 1024) (112, 1024)    
HBsAg ≥10 390 362 0.001* 358 311 0.098 0.349 0.570
(IU/ml)  (282, 537) (212, 468)  (247, 418) (232, 412)    
Dtx ≥0.01 1.39 1.19 0.043 1.73 1.46 0.0011* 0.043 0.105
(IU/ml)  (0.8, 1.8) (0.8, 1.7)  (1.4, 2.2) (1.0, 2.1)    
Ttx ≥0.01 3.71 3.39 0.422 3.03 2.54 0.0053* 0.762 0.376
(IU/ml)  (1.8, 5.6) (1.4, 5.4)  (1.9, 4.5) (1.5, 3.4)    
Hib ≥0.15 5.88 6.37 0.197 8.21 7.95 0.257 0.762 0.671
(µg/ml)  (2.1, 23.8) (2.4, 24.8)  (3.0, 15.7) (3.1, 17.6)    
Antibody responses to the EPI vaccines OPV (Poliovirus 1), HBV (HBsAg), diphtheria toxin (Dtx), tetaus toxin (Ttx) and Hib. Median values are shown with interquartile
range in brackets below. Wilcoxon matched pairs analysis was used to compare 19 and 21 week responses for the same infants; 2-tailed Mann-Whitney U tests were used
to compare vaccine and control groups. Significant p values are indicated in bold type, * indicates significance after Bonferroni correction. Vac - vaccine group; Con - control
group.
doi: 10.1371/journal.pone.0078289.t005
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Indeed, there are no widely accepted normal values for infants
in sub-Saharan Africa and this study contributes towards
establishing such reference ranges [42-45].
One low-dose administration of MVA.HIVA was marginally
immunogenic by fresh IFN-γ ELISPOT assay frequencies,
whereby only 9% of vaccinated infants developed detectable
HIV-1-specific T-cell responses. Group analysis showed
statistically significant responses to 1 of 2 tested peptide pools
1 week after MVA.HIVA administration, which concurs with the
timing of peak responses observed in adult vaccinees [29].
Thus, MVA.HIVA administered alone was not sufficiently
immunogenic. This was not totally unexpected. First, PedVacc
001 used a very prudent infant safety approach in
administering a single low dose of the MVA.HIVA vaccine
compared to 4 doses used in the other infant vaccine studies,
which elicited lymphoproliferative, rare cytotoxic T-cell and
Env-specific Ab responses [12-14,16,17,19]. Second, MVA-
vectored vaccines are not strong primers of T-cell responses
and as such are typically used for boosting in heterologous
prime-boost regimens. In contrast after either a DNA prime or
in HIV-1-infected volunteers on HAART, all MVA.HIVA
recipients developed vaccine-stimulated responses
[27-29,31,46-48]. In 2007 when the PedVacc 001 trial was
conceived, we envisaged a strategy administering MVA.HIVA
boost to 20-week-old infants who have been primed at birth
with HIVA-expressing Mycobacterium bovis bacillus Calmette-
Guérin (BCG) [49,50]. Moreover, encouraged by then
promising results of candidate TB vaccine MVA85A [51], there
was a possibility to develop the BGC-MVA regimen into a dual
HIV-TB vaccine platform [24,25,52-56]. Since the
commencement of PedVacc 001, both the immunogen design
and vector delivery evolved. Thus, we showed that a prime with
non-replicating recombinant adenovirus of chimpanzee origin
followed by a boost with recombinant MVA induced uniquely
high frequencies of HIV-1-specific T cells in UK adults [57]. As
for the immunogen, HIVA has been superseded by universal
pan-clade immunogen HIVconsv, which is based on the 14
most conserved regions of the HIV-1 proteome to tackle HIV-1
diversity and escape [57-59]. Furthermore, we plan to include
component(s) inducing broadly neutralizing antibodies into the
final vaccine regimen when these become available. Thus,
although further clinical development of the MVA.HIVA vaccine
has now ceased, safety demonstrated in PedVacc 001 builds
confidence for future use of the MVA vector in heterologous
vaccine strategies in this age group in Africa.
A single MVA.HIVA dose administered 4 weeks after the
busy EPI vaccine period did not significantly affect the
immunogenicity of EPI vaccines, nor influenced the number of
infants with vaccine antibody titers above protective levels. This
agrees with the results from 3 previous HIV-1-vaccine studies
[13,16,19]. Notably, a reduction of MVA85A immunogenicity in
Gambian infants was reported when co-administered with EPI
[40].
Overall, this small phase I trial demonstrates that challenges
associated with studies in infants such as obtaining ethical and
regulatory approvals, logistics of recruiting and retaining
mother-infant pairs and working with small blood volumes for
immune assays can be overcome. As part of the trial conduct,
infrastructure improvements significantly increased the capacity
and daily efficiency of the health centre in Sukuta, including
provision of laboratory, GCP, data and project management
training. Thus, PedVacc 001 represents another cumulative
step towards developing a prime-boost vaccine regimen aimed
at reducing the transmission of HIV-1 during breast-feeding.
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